Quick Answer
Dermata Therapeutics, Inc. reported Research And Development Expense of $2.93 million for the year ending 2025.
- Dermata Therapeutics, Inc. showed a decrease of -64.3% in Research And Development Expense from 2024 to 2025.
- This data is from Dermata Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Dermata Therapeutics, Inc.'s Research And Development Expense has grown by 82.2%.
- Historical annual values: Fiscal year 2025: $2.93 million | Fiscal year 2024: $8.20 million | Fiscal year 2023: $4.07 million | Fiscal year 2022: $5.65 million | Fiscal year 2021: $3.46 million | Fiscal year 2020: $1.61 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: